ArticleMolecular biology reports2025
A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial translational control in cardiovascular diseases: from mechanisms to therapies.Redox biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic heart disease with a wide range of clinical manifestations, from asymptomatic cases to heart failure and sudden cardiac death.
objectivesTo identify the disease-causing variants in patients with severe HCM by carrying on clinical examination and genetic analysis through 2 generations in a single family. PATIENTS AND
methodsFamily 'members underwent comprehensive cardiovascular examinations. Whole-exome sequencing was carried on the proband, a girl of five-years old followed by co-segregation and in silico analyses.
resultsThe proband harboured a homozygous variant, NM_022915.5: c.198_205delinsTA; p.(Trp66_His69 delinsCysAsn), in the MRPL44 gene, leading to a shorter protein. This variant is novel, being absent in ClinVar and Human Gene Mutation Database (HGMD) and classified as VUS according to American College of Medical Genetics and Genomics (ACMG) criteria. Co-segregation analyses revealed that the proband's parents and her sister were heterozygous carriers, her other sister was wild-type, and her affected brother was homozygous for the mutation. In silico analysis showed significant structural differences in the mutated mL44 protein, disrupting its interaction with ribosomal complex components and impairing translation and protein synthesis.
conclusionsThis study reports a novel MRPL44 variant associated with HCM in a Tunisian family. This finding expands current knowledge of genetic variations linked to mitochondrial cardiomyopathy and highlights the importance of genetic testing for diagnosis and management of cardiomyopathy.
Indexed as
Identifiers
40402202What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.